EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease

Marc Arbyn; Silvia de Sanjosé; Mona Saraiya; Mario Sideri; Joel Palefsky; Charles Lacey; Maura Gillison; Laia Bruni; Guglielmo Ronco; Nicolas Wentzensen; Julia Brotherton; You-Lin Qiao; Lynnette Denny; Jacob Bornstein; Laurent Abramowitz; Anna Giuliano; Massimo Tommasino; Joseph Monsonego

doi:10.1002/ijc.27650

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease

Marc Arbyn, Silvia de Sanjosé, Mona Saraiya, Mario Sideri, Joel Palefsky, Charles Lacey, Maura Gillison, Laia Bruni, Guglielmo Ronco, Nicolas Wentzensen, Julia Brotherton, You-Lin Qiao, Lynnette Denny, Jacob Bornstein, Laurent Abramowitz, Anna Giuliano, Massimo Tommasino, Joseph Monsonego

The Hull York Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

The EUROGIN 2011 roadmap reviews the current burden of HPV (human papillomavirus)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes approximately 600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomised trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programmes. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, ano-genital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organised approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.

Original language	English
Pages (from-to)	1969-1982
Number of pages	14
Journal	International Journal of Cancer
Volume	131
Issue number	9
DOIs	https://doi.org/10.1002/ijc.27650
Publication status	Published - 1 Nov 2012

Access to Document

10.1002/ijc.27650

Cite this

Arbyn, M., Sanjosé, S. D., Saraiya, M., Sideri, M., Palefsky, J., Lacey, C., Gillison, M., Bruni, L., Ronco, G., Wentzensen, N., Brotherton, J., Qiao, Y.-L., Denny, L., Bornstein, J., Abramowitz, L., Giuliano, A., Tommasino, M., & Monsonego, J. (2012). EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. International Journal of Cancer, 131(9), 1969-1982. https://doi.org/10.1002/ijc.27650

@article{73f80d5bdf6647799f3a6cbb110b0a58,

title = "EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease",

abstract = "The EUROGIN 2011 roadmap reviews the current burden of HPV (human papillomavirus)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes approximately 600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomised trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programmes. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, ano-genital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organised approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.",

author = "Marc Arbyn and Sanjos{\'e}, {Silvia de} and Mona Saraiya and Mario Sideri and Joel Palefsky and Charles Lacey and Maura Gillison and Laia Bruni and Guglielmo Ronco and Nicolas Wentzensen and Julia Brotherton and You-Lin Qiao and Lynnette Denny and Jacob Bornstein and Laurent Abramowitz and Anna Giuliano and Massimo Tommasino and Joseph Monsonego",

note = "Copyright {\textcopyright} 2012 UICC.",

year = "2012",

month = nov,

day = "1",

doi = "10.1002/ijc.27650",

language = "English",

volume = "131",

pages = "1969--1982",

journal = "International Journal of Cancer",

issn = "1097-0215",

publisher = "Wiley-Blackwell",

number = "9",

}

Arbyn, M, Sanjosé, SD, Saraiya, M, Sideri, M, Palefsky, J, Lacey, C, Gillison, M, Bruni, L, Ronco, G, Wentzensen, N, Brotherton, J, Qiao, Y-L, Denny, L, Bornstein, J, Abramowitz, L, Giuliano, A, Tommasino, M & Monsonego, J 2012, 'EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease', International Journal of Cancer, vol. 131, no. 9, pp. 1969-1982. https://doi.org/10.1002/ijc.27650

TY - JOUR

T1 - EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease

AU - Arbyn, Marc

AU - Sanjosé, Silvia de

AU - Saraiya, Mona

AU - Sideri, Mario

AU - Palefsky, Joel

AU - Lacey, Charles

AU - Gillison, Maura

AU - Bruni, Laia

AU - Ronco, Guglielmo

AU - Wentzensen, Nicolas

AU - Brotherton, Julia

AU - Qiao, You-Lin

AU - Denny, Lynnette

AU - Bornstein, Jacob

AU - Abramowitz, Laurent

AU - Giuliano, Anna

AU - Tommasino, Massimo

AU - Monsonego, Joseph

PY - 2012/11/1

Y1 - 2012/11/1

N2 - The EUROGIN 2011 roadmap reviews the current burden of HPV (human papillomavirus)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes approximately 600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomised trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programmes. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, ano-genital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organised approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.

AB - The EUROGIN 2011 roadmap reviews the current burden of HPV (human papillomavirus)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes approximately 600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomised trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programmes. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, ano-genital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organised approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.

UR - http://www.scopus.com/inward/record.url?scp=84865559165&partnerID=8YFLogxK

U2 - 10.1002/ijc.27650

DO - 10.1002/ijc.27650

M3 - Article

C2 - 22623137

SN - 1097-0215

VL - 131

SP - 1969

EP - 1982

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 9

ER -

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease

Abstract

Access to Document

Other files and links

Cite this